10780432ccr082905-sup-relatedarticle.html (0.87 kB)

Related Article from Evaluation of T- and NK-Cell-Targeted Therapies: Is There a Role for Rituximab Prophylaxis?

dataset

posted on 2023-03-31, 15:41 authored by Richard F. Ambinder

History

ARTICLE ABSTRACT

Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.